In today’s briefing:
- China Healthcare Weekly (Aug.17) – GLP-1s Inflection Point, Novartis to Acquire Avidity Biosciences
- IDEXX Laboratories Hits 10
- Moderna Inc Expands Beyond Respiratory Vaccines – Is Diversification the Key to Long-Term Success?
- Vertex Pharmaceuticals: Will Its Growth of JOURNAVX Be A Critical Breakthrough?
China Healthcare Weekly (Aug.17) – GLP-1s Inflection Point, Novartis to Acquire Avidity Biosciences
- Based on 25Q2 sales data of Semaglutide and Tirzepatide, the penetration rate of both T2D and weight loss indications is approaching ceiling. The inflection point of GLP-1 market has arrived.
- When the gap of clinical progress in EU/US markets is too large, these drugs may not even be on the same tier, and thus do not constitute substantive competition.
- Novartis has approached Avidity Biosciences with an acquisition offer. We think price range of $9-11B is justified by 3-5x peak sales multiples and strategic urgency.
IDEXX Laboratories Hits 10
- IDEXX Laboratories, Inc. reported robust financial results for the second quarter of 2025, underpinned by strong execution, particularly in their Companion Animal Group (CAG) business.
- The company’s revenue increased 11% as reported and 9% organically.
- Growth was driven notably by advancements in their CAG Diagnostic Recurring Revenues, which benefited from significant CAG instrument sales and a strong international performance.
Moderna Inc Expands Beyond Respiratory Vaccines – Is Diversification the Key to Long-Term Success?
- The earnings report for Moderna, Inc.’s second quarter of 2025 presents a multifaceted picture of the company’s current financial health and strategic endeavors.
- Beginning with the financial landscape, Moderna reported revenues of $2.1 billion and experienced a loss of $0.8 billion, which aligns with the company’s expectations given the seasonal nature of its respiratory vaccine business.
- Notably, the company managed to reduce its cost of sales and SG&A by 35% compared to the previous year, indicating a strong commitment to financial discipline.
Vertex Pharmaceuticals: Will Its Growth of JOURNAVX Be A Critical Breakthrough?
- Vertex Pharmaceuticals reported strong performance in the second quarter of 2025, achieving a 12% year-overyear revenue growth, reaching $2.96 billion.
- This growth was driven by the successful commercialization of multiple new products and the expansion of its existing portfolio in treating cystic fibrosis (CF), sickle cell disease, beta thalassemia, and acute pain.
- On the positive side, Vertex Pharmaceuticals made significant strides in the CF market with the introduction of ALYFTREK, which is showing promising adoption across the United States and Europe.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
